Authors

Monica Fradkin, RN, BSN, MPH, OCN,and Elizabeth Blasiak, RN, MSN, OCN

Latest:

Journal Club Bridges Research and Practice, Improving Patient Care

Three oncology nurses at the Smilow Cancer Hospital at Yale-New Haven write about the Smilow Society, an interactive and innovative journal club enabling nurses to stay abreast of important research developments, which can then be translated directly into clinical practice.

Monica Morrow, MD

Latest:

Dr. Morrow on Patient Selection for Nipple Sparing Mastectomy

Monica Morrow, MD, discusses the factors that impact the decision to use nipple sparing mastectomy versus conventional mastectomy in patients with breast cancer. The decision to use a nipple sparing approach in patients is dependent on 2 considerations. These relate to the cancer as well as cosmetic appearance of the breast.

Monika Joshi, MD

Latest:

Dr. Joshi on Rationale for Durvalumab/RT Combo in Localized Urothelial Carcinoma

Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.

Moon Chen, PhD

Latest:

Initiative Aims to Boost Clinical Trial Participation Among Asian-Americans

The UC Davis Comprehensive Cancer Center and the National Cancer Institute (NCI)-funded National Center for Reducing Asian American Cancer Health Disparities are working to address these disparities through programs to boost participation in clinical trials, collect biospecimens, and conduct blood genomics research.

Moon S. Chen, Jr., PhD

Latest:

Moon Chen on Disparities in Cancer Care

Moon S. Chen Jr., PhD, MPH, associate director, Population Research and Cancer Disparities, professor, UC Davis Comprehensive Cancer Center, discusses various disparities in cancer care in underserved populations.

Morey Blinder, MD Washington University

Latest:

Future Directions in the Management of Immune Thrombocytopenia

Expert panelists reflect on the advent of newer therapies in immune thrombocytopenia and look toward future evolutions in care.

Morgan E. Meissner, PhD

Latest:

NY-ESO-1 Gains Momentum as a Therapeutic Target

As the immunotherapy research field grows, NY-ESO-1 is emerging as a high-priority target for cancer vaccine development and adoptive T-cell therapies.

Morgan Meisner, PhD

Latest:

Triplet Targeted Therapy May Signal a New Standard in Metastatic CRC

Now, investigators are combining BRAF inhibitors with other targeted therapies in an effort to establish a new chemotherapy-free standard in patients with metastatic colorectal cancer.

Morgane C. Diven, PharmD

Latest:

Denosumab: A Review of Its Pharmacology and Clinical Implications

It is estimated that approximately 80% of all patients with diagnoses of breast cancer, prostate cancer, or multiple myeloma will develop bone metastases at some time during the course of their disease.

Morganna Freeman, DO

Latest:

Dr. Freeman on Challenges in Treatment Selection in Melanoma

Morganna Freeman, DO, associate director, Melanoma and Cutaneous Oncology Program, The Angeles Clinic and Research Institute, discusses the challenges associated with treatment selection in melanoma.

Morganna Freeman, DO, FACP

Latest:

Where There’s Smoke: Are Oncology Fellows in Danger of Burnout?

This moment occurred during the middle of my first year of fellowship, and I felt overwhelmed by clinical responsibilities and a seemingly insurmountable learning curve. The question dawned on me: was I suffering from burnout?

Morganna Freeman- Keller, DO, PGY5

Latest:

Becoming a Champion of Change: Educating Fellows on the Costs of Cancer Care

On a recent day in hematology clinic, I stood dutifully by my attending as he sorted through bone marrow slides

Morie A. Gertz, MD, MACP

Latest:

Dr. Gertz on the Outlook for Waldenstrom Macroglobulinemia

Morie A. Gertz, MD, MACP, discusses the current outlook for patients with Waldenström macroglobulinemia.

Morie Gertz, MD

Latest:

Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.

Morris Sherman, MD

Latest:

Dr. Sherman on the Role of Regorafenib in Liver Cancer

Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Morris Sherman, MD, PhD

Latest:

Dr. Sherman on Screening Obstacles in Liver Cancer

Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the issues oncologists face with screening patients for hepatocellular carcinoma (HCC) in an interview during the 10th International Liver Cancer Association (ILCA) Annual Conference.

Moshe Ornstein, MD

Latest:

Optimizing Treatment in Advanced RCC

Martin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.

Moshe Talpaz, MD, University of Michigan Health System

Latest:

Future Management of Chronic Myeloid Leukemia

Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.

Mothaffar F. Rimawi, MD

Latest:

Dr. Rimawi on the Promise of the HER2CLIMB-02 Trial in HER2+ Breast Cancer

Mothaffar Fahed Rimawi, MD, discusses the promise of the phase 3 HER2CLIMB-02 trial in HER2-positive metastatic breast cancer.

Motzer RJ, Escudier B, Oudard S, et al.

Latest:

Everolimus Improves Progression-Free Survival in Patients with Previously Treated Metastatic RCC

A subgroup analysis of a randomized trial showed that patients with previously treated metastatic renal cell carcinoma had significant improvement in progression-free survival when they received everolimus.